Neptune Technologies & Bioressources Inc. Subsidiary Acasti Pharma Inc. Welcomes Dr. Jean Davignon to Its Scientific Advisory Bo
27 January 2011 - 12:00AM
Neptune Technologies & Bioressources Inc. ("Neptune")
(Nasdaq:NEPT) (TSX-V:NTB) subsidiary Acasti Pharma Inc. ("Acasti")
are pleased to announce the expansion of Acasti's Scientific
Advisory Board (SAB) by welcoming Pr. Jean Davignon OC, GOQ, MD,
MSc, FRCPC, FACP, FRSC, FACN, FAHA, FCAHS, to join Dr. Jacques
Genest (McGill University), Dr. Steven Nissen (Cleveland Clinic),
Pr. Ruth McPherson (University of Ottawa), Pr. William Harris
(Sandford Research/USD), Pr. Thomas G. Hartman (Rutgers University
Center) and Dr. Magdy M. Abdel-Malik (Quaestio Global Partners).
Dr. Jean Davignon is the founding member of the Canadian
Atherosclerosis Society, the Canadian Association for Familial
Hypercholesterolemia and the Canadian Institute of Academic
Medicine. Dr. Davignon was the Director of the Hyperlipidemia and
Atherosclerosis Research Unit at the Institut de recherches
cliniques de Montreal (IRCM) from 1967 until 2008 where he was
appointed Emeritus Researcher in 2009. He is currently Emeritus
Physician at the Hotel-Dieu Hospital in Montreal, Professor at the
Faculty of Medicine at the Universite de Montreal and Adjunct
Professor in the Department of Experimental Medicine at McGill
University. He practices in the field of lipidology at the
Nutrition, Metabolism and Atherosclerosis Clinic which he founded
at IRCM in 1967.
Recipient of numerous awards and achievements from many
outstanding organizations including the Markle Scholar in Academic
Medicine (1967-1972), "Coeur Quebec Or" from the Quebec Heart and
Stroke Foundation and the FNG Starr Award of the Canadian Medical
Association (1993). In 1995, Dr. Davignon was made an Officer of
the Order of Canada, Canada's highest civilian honor. In 2006, he
was made a Grand Officer of the National Order of Quebec; in 2000,
he was awarded the Quebec Government's Prix Wilder-Penfield and in
1995, he was made a Fellow of the Royal Society of Canada. He also
received a doctorate Honoris Causa from Universite Paul Sabatier,
Toulouse, France (1992), and the Grande Medaille d'Or du Centenaire
from the Institut Pasteur of Lille, France (1994). The Jean
Davignon Distinguished Cardiovascular and Metabolic Research Award,
sponsored by Pfizer, was created in 2006.
"Acasti Pharma continues to demonstrate its dedication to
excellence by welcoming Dr. Jean Davignon, a world renowned
clinician-scientist in the field Hyperlipidemia and
Atherosclerosis," said Dr. Farhad Amiri, Director, Preclinical
Studies, Acasti Pharma Inc. "We are honored to have the opportunity
to work with Dr. Davignon and benefit both from his expertise and
knowledge in the development of our multiple products currently in
our pipeline," he added.
"It is with great honor and respect that we welcome Dr. Jean
Davignon as a member of our Scientific Advisory Board," said Dr.
Tina Sampalis, President of Acasti Pharma Inc. "We are extremely
proud to have attracted someone of the caliber of Dr. Davignon to
our team completing the esteemed group of scientific experts
guiding our efforts. Dr. Jean Davignon brings expertise on core
aspects of Acasti's product development," she added. "Overall, we
have made considerable progress to date in Acasti; we are ready to
initiate our first Phase II clinical study with CaPre™, Acasti's
drug candidate, while launching our first medical food Onemia™ in
the United States and advancing on the commercialization of
Acasti's fixed dose combination over the counter product Vectos™,"
added Dr. Sampalis.
"I am pleased and honored to join the scientific advisory board
of Acasti Pharma Inc. as their drug development program is
promising, at the leading-edge and raises many important
mechanistic questions," commented Dr. Jean Davignon.
About Neptune Technologies & Bioressources
Inc.
Neptune is an industry-recognized leader in the innovation,
production and formulation of science-based and clinically proven
novel phospholipid products for the nutraceutical and
pharmaceutical markets. The Company focuses on growing consumer
health markets including cardiovascular, inflammatory and
neurological diseases driven by consumers taking a more proactive
approach to managing health and preventing disease. The Company
sponsors clinical trials aimed to demonstrate its product health
benefits and to obtain regulatory approval for label health claims.
Neptune is continuously expanding its intellectual property
portfolio as well as clinical studies and regulatory approvals.
Neptune's products are marketed and distributed in over 20
countries worldwide. Neptune is the mother company of Acasti and
NeuroBioPharm.
About Acasti Pharma Inc.
Acasti Pharma is developing a product portfolio of proprietary
novel long-chain omega-3 phospholipids. Phospholipids are the major
component of cell membranes and are essential for all vital cell
processes. They are one of the principal constituents of High
Density Lipoprotein (good cholesterol) and, as such, play an
important role in modulating cholesterol efflux. Acasti Pharma's
proprietary novel phospholipids carry and functionalize the
polyunsaturated omega-3 fatty acids EPA and DHA, which have been
shown to have substantial health benefits and which are stabilized
by potent antioxidants. Acasti Pharma is focusing initially on
treatments for chronic cardiovascular conditions within the
over-the-counter, medical food and prescription drug markets.
About NeuroBioPharm Inc.
NeuroBioPharm is pursuing pharmaceutical neurological
applications, and a clinical study for a medical food product with
a multinational partner is already initiated. The development of a
prescription drug candidate is currently in progress. Advanced
clinical development and commercialization is planned to be carried
out with multinational partners.
"Neither Nasdaq nor the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release."
Statements in this press release that are not statements of
historical or current fact constitute "forward-looking statements"
within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995 and Canadian securities laws. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other unknown factors that could cause the
actual results of the Company to be materially different from
historical results or from any future results expressed or implied
by such forward-looking statements. In addition to statements which
explicitly describe such risks and uncertainties, readers are
urged to consider statements labeled with the terms "believes,"
"belief," "expects," "intends," "anticipates," "will," or
"plans" to be uncertain and forward-looking. The forward-looking
statements contained herein are also subject generally to other
risks and uncertainties that are described from time to time in the
Company's reports filed with the Securities and Exchange Commission
and the Canadian securities commissions.
CONTACT: Neptune Contact:
Neptune Technologies & Bioressources Inc.
Andre Godin, V.P. Administration and Finance
+1 450.687.2262
a.godin@neptunebiotech.com
www.neptunebiotech.com
Acasti Contact
Acasti Pharma Inc.
Tina Sampalis, President
+1 450.686.4555
t.sampalis@acastipharma.com
www.acastipharma.com
CEOcast Contact:
Dan Schustack
+1 212-732-4300
dschustack@ceocast.com
www.ceocast.com
Howard Group Contact:
Bob Beaty
1 (888) 221-0915
bob@howardgroupinc.com
www.howardgroupinc.com
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Jun 2024 to Jul 2024
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Jul 2023 to Jul 2024